ERVW-1 and neoplasm: Some common modifications for improved viral entry include (a) replacement of the original viral fibre with a viral fibre of the desired tumour tropism (serotype switching), (b) modification of viral capsid proteins or viral envelope glycoproteins for improved viral entry and (c) insertion of genes encoding a single-chain antibody specific to a known tumour-surface antigen [36].